Pharmaceuticals

Company strengthens Board in anticipation of strong commercial growth phase

[PRESSWIRE] Nottingham, UK – June 4th, 2024 — 4D Medicine Limited has appointed Dr Tom Buckland as its new Chairman and Non-executive Director.

Nexus Pharmaceuticals Receives FDA Approval for Tranexamic Acid in 0.7% Sodium Chloride Injection

[PRESSWIRE] Lincolnshire, IL – 18 April, 2024 — Nexus Pharmaceuticals announced the FDA approval of Tranexamic Acid in 0.7% Sodium Chloride Injection, a new addition to their generic injectable portfolio. Tranexamic Acid in 0.7% Sodium Chloride is an intravenous antifibrinolytic indicated for short term use in hemophilia patients to promote healthy blood clotting following various procedures.

NarcX+ First to Meet DEA Standards for Destroying Illicit Fentanyl and Rendering It Non-Retrievable

[PRESSWIRE] VINEYARD, Utah – 12.01.24 — NarcX Solutions, Inc., a Utah-based company and rapidly rising innovator for on-site drug disposal, announces a major milestone in the fight against Illicit Fentanyl.

AbolerIS Pharma Announces €27.3 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases

[PRESSWIRE] Belgium – 18.09.23 — AbolerIS Pharma (“AbolerIS”), a biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, today announced a €27.3 million Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with participation from SFPI-FPIM, WE, Sambrinvest, Investsud Tech, and Relyens Innovation Santé/Turenne Capital. Proceeds from the financing will enable AbolerIS to accelerate the development of its lead program in clinical trials and explore its effectiveness in additional autoimmune diseases.

CEBINA Announces Positive Results of a Phase 2 Clinical Study with COVID-19 patients and Azelastine Nasal Spray Published in a Peer-Reviewed Scientific Journal

[PRESSWIRE] Vienna, Austria – 02.05.2003 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of the positive results of a Phase 2 clinical study that tested azelastine nasal spray as a new approach for reducing viral load in the nose of SARS-CoV-2 positive patients in the peer-reviewed journal Scientific Reports (1).

Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023

PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies Greater selectivity of PMN310 for toxic oligomers indicates a potentially differentiated profile and supports further development

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 13, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that new preclinical data for ProMIS’ lead candidate for AD, PMN310, will be presented as a virtual short oral poster presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023) to be held on March 28-April 1, 2023 virtually and in Gothenburg, Sweden.

ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – November 14, 2022 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its third quarter 2022 financial results and recent highlights.

ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – November 14, 2022 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its third quarter 2022 financial results and recent highlights.

CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by major variants of SARS-CoV-2

[PRESSWIRE] Austria – 04.07.22 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of research results demonstrating that the commonly used anti-histamine, azelastine, is a potent inhibitor of major variants of SARS- CoV-2 in the peer-reviewed journal Frontiers in Pharmacology (1).

PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, MA, June 27, 2022 — ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that, to meet the criteria to list its common shares on the Nasdaq Capital Market (“NASDAQ”), the Board of Directors has approved a 1-for-60 reverse share split (the “Reverse Split”), of the Company’s issued and outstanding common shares.

Kosmik Brands Launches in Planet 13

[PRESSWIRE] EDMOND, OKLAHOMA – MAY 24, 2022 — IRIS JUNE / Soon after Kosmik Brands launched in the great state of Nevada, they are back with more exciting news. Planet 13, globally recognized as the largest cannabis dispensary in the world, now carries all Kosmik products. Setting the world record with their opening back in 2018, since day one, Planet 13 continues to set the bar higher than any other facility when it comes to customer experience. Here’s what’s in store.

NemaLife and UC Davis enter into a research partnership to test the therapeutic potential of several novel psychoplastogens developed in David E. Olson’s Lab

[PRESSWIRE] LUBBOCK, TX — April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.

Freedom to Operate Publishes Open Letter to Compass Pathways Challenging Validity of Psilocybin Patent

[PRESSWIRE] Greenwich, Connecticut – April 14, 2022 — The non-profit, Freedom to Operate (FTO), has just published an open letter to Compass Pathways’ CEO, George Goldsmith, regarding the invalidity of one of Compass’ U.S. patents on psilocybin.

ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, MA —March 24, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it will be presenting at the upcoming 10th Annual Neurodegenerative Drug Development Summit, to be held in Boston, MA, March 28-30, 2022.

ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer’s Vaccine at the 2022 International AD/PDTM Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. —March 22, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today in vivo results of its experimental Alzheimer’s vaccine presented at the AD/PDTM International Conference held in Barcelona Spain, March 15-20, 2022.

ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. —March 10, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it will be presenting at the upcoming AD/PDTM International Conference, to be held in Barcelona Spain, March 15-20, 2022.

Eveliqure announces the publication of positive Phase I clinical data for its vaccine candidate against Shigellosis and ETEC

[PRESSWIRE] Vienna – 23rd February 2022 — Eveliqure Biotechnologies GmbH, a clinical stage biotechnology company, today announces the publication of positive Phase I data with ShigETEC, its vaccine candidate against Shigellae and enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines10020340).

Azelastine – the active drug in anti-allergy nasal sprays demonstrated to have potent anti-viral effect on the Omicron variant of SARS-CoV-2

[PRESSWIRE] Vienna – 03 February, 2022 — CEBINA GmbH, Central European Biotech Incubator and Accelerator with its partner URSAPHARM Arzneimittel GmbH, today announce new results demonstrating that azelastine, the active drug in Pollival®, URSAPHARM’s widely available anti-allergy nasal spray, is an effective anti-viral against the globally dominant omicron SARS-CoV-2 variant in laboratory conditions.

ProMIS Neurosciences to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. — January 6, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10–13, 2022.

CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant

[PRESSWIRE] Austria – 10.12.21 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today informs about the potential of the antihistamine drug azelastine hydrochloride to be an effective anti-viral approach against major respiratory viruses, such as SARS-CoV-2 and its variants, influenza and Respiratory Syncytial Virus (RSV).

European Campaign gives Kidneys a stage! ERA-EDTA launches the European Kidney Health Awareness Days

[PRESSWIRE] Parma, Italy – 05 May, 2021 — One in ten adults in Europe suffer from reduced kidney function and yet many will be unaware of this. What is fatal is that the loss of kidney function cannot be reversed. It is therefore essential that the general public are made aware of the importance of the kidneys and how to protect them.

CEBINA reports potency of azelastine against emerging dominant variants of SARS-CoV-2 in laboratory testing

[PRESSWIRE] Austria – 04 May, 2021 — CEBINA GmbH, an Austrian biotech company, today announces that azelastine, previously identified as a potential anti-COVID-19 drug, is equally potent against newly emerging dominant variants of SARS-CoV-2 compared to the original virus. Azelastine is available as an anti-allergy nasal spray and is currently being tested in a Phase 2 efficacy trial for the treatment of early-stage COVID-19 disease.

URSAPHARM Arzneimittel and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19

[PRESSWIRE] Vienna, Austria – 17 February, 2021 — In the fight against the SARS-CoV-2 virus, a large number of pharmaceutical companies are looking for new approaches to combat the pandemic. In addition to vaccines, intensive research and development efforts around the world are focusing on identifying new anti-COVID therapeutics that includes re-evaluation of existing product portfolios with a view to re-purpose drugs that have antiviral properties.

Danish MedTech start-up disrupts the global market for eye care

[PRESSWIRE] Denmark – 14 December, 2020 — Many challenges are associated with the conventional eye drop bottle. The global ophthalmic industry has long pushed for a way to better deliver medication to the eye. Now, the Danish-based MedTech start-up, EYE-GO, has the solution that can improve the lives of millions of people globally suffering from dry eyes and other chronic eye conditions. Leading ophthalmologists and frontrunning international players in the industry have already named it “a true game-changer in eye care”. The Danish state participated in the latest funding round.

Eveliqure announces the publication of key preclinical data for its clinical stage vaccine candidate against Shigellosis and ETEC

[PRESSWIRE] Austria – 19.11.20 — Eveliqure Biotechnologies GmbH, a clinical-stage biotechnology company, today announces the publication of preclinical data with ShigETEC, its vaccine candidate against Shigellae and Enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines8040689).

Eveliqure announces the initiation of a Phase 1 clinical study of its combined Shigella and ETEC vaccine candidate

[PRESSWIRE] Austria – 24 September, 2020 — Eveliqure Biotechnologies GmbH, an Austrian biotechnology company, today announces the initiation of clinical testing for its ShigETEC vaccine candidate, with the dosing of the first subject in a Phase 1 safety and immunogenicity study in Europe.

B Medical Systems Opens US Subsidiary in Indiana

[PRESSWIRE] US – 19 September, 2020 – B Medical Systems, a leading European medical refrigeration and global vaccine cold chain manufacturer, is pleased to announce the official opening of its new 10,000 sq ft sales office and warehouse in Noblesville, Indiana. With over 40 years of experience in the medical refrigeration and vaccine cold chain market, the company offers a full line of medical-grade refrigerators, freezers, ultra-low temperature freezers, and transport devices designed for the safe storage and transport of biological materials, critical samples, blood, and vaccines.

Complete contents of Recipharm’s Ashton-under Lyne pharmaceutical manufacturing facility under the hammer

[PRESSWIRE] London, United Kingdom – 13 August, 2020 — Global liquidation specialists Maynards Europe and Liquidity Services are to sell the complete contents of Recipharm’s Ashton-under-Lyme pharmaceutical facility by online auction on October 22. The project will include logistics partners offering turnkey solutions to relocate and recommission equipment globally.

Kanabo und Simply Green wollen gemeinsam reine Hanf-CBD-Rezepturen zusammen mit dem ersten Dosierverdampfer auf den deutschen Markt bringen

[PRESSWIRE] Israel – 13 August, 2020 — Kanabo Research LTD und Simply Green BV haben eine exklusive Vertriebsvereinbarung unterzeichnet, um die medizinische Verdampfungstechnologie von Kanabo auf den deutschen Markt zu bringen. Im Rahmen der Vereinbarung erhält Simply Green das exklusive Vertriebsrecht für die proprietäre Lieferplattform Kanabo VapePod® und Rezepturen über dessen Vertriebsnetz.